NASDAQ:ETON Eton Pharmaceuticals (ETON) Stock Price, News & Analysis $37.50 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$37.85 +0.35 (+0.93%) As of 07/2/2026 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eton Pharmaceuticals Stock (NASDAQ:ETON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eton Pharmaceuticals alerts:Sign Up Key Stats Today's Range$36.63▼$37.9750-Day Range$22.97▼$37.5052-Week Range$13.76▼$37.97Volume526,790 shsAverage Volume393,212 shsMarket Capitalization$1.03 billionP/E RatioN/ADividend YieldN/APrice Target$41.00Consensus RatingHold Company Overview Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings. The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis. Eton gained U.S. Food and Drug Administration approval for several abbreviated new drug applications (ANDAs) and new drug applications (NDAs), enabling it to bring both generic and specialty branded medicines to market. Its development pipeline features additional hormone replacement therapies and other complex dosage forms intended to broaden its reach in endocrine and rare disease markets. Eton Pharmaceuticals serves patients and healthcare providers across the United States through strategic partnerships with wholesalers, specialty pharmacies and healthcare institutions. The company employs a network of contract manufacturing organizations to ensure product quality and supply chain efficiency. With a focus on regulatory compliance, timely product launches and niche market development, Eton continues to pursue opportunities that align with its mission of improving care for patients with limited treatment options.AI Generated. May Contain Errors. Read More Eton Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreETON MarketRank™: Eton Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 493rd out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingHold Consensus RatingEton Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Eton Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageEton Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Eton Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth154.67% Earnings GrowthEarnings for Eton Pharmaceuticals are expected to grow by 154.67% in the coming year, from $0.75 to $1.91 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eton Pharmaceuticals is -535.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eton Pharmaceuticals is -535.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEton Pharmaceuticals has a P/B Ratio of 38.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eton Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.23% of the float of Eton Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEton Pharmaceuticals has a short interest ratio ("days to cover") of 4.13.Change versus previous monthShort interest in Eton Pharmaceuticals has recently increased by 13.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEton Pharmaceuticals does not currently pay a dividend.Dividend GrowthEton Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News SentimentN/A News SentimentEton Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Eton Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest15 people have searched for ETON on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows6 people have added Eton Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Eton Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,853,921.00 in company stock.Percentage Held by Insiders16.49% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions27.86% of the stock of Eton Pharmaceuticals is held by institutions.Read more about Eton Pharmaceuticals' insider trading history. Receive ETON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ETON Stock News HeadlinesEton Pharmaceuticals (NASDAQ:ETON) Director Jennifer Mckie Adams Sells 50,000 SharesJune 18, 2026 | insidertrades.comEton Shareholders Back Board Nominees and Auditor SelectionJune 9, 2026 | tipranks.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.July 5 at 1:00 AM | Banyan Hill Publishing (Ad)Eton Pharmaceuticals Inc (ETON) Shares Fall 4.3% -- What GF Score of 70 Tells InvestorsMay 29, 2026 | gurufocus.comH.C. Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth StrategyMay 23, 2026 | finance.yahoo.comEton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)May 19, 2026 | globenewswire.comEton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen NextMay 16, 2026 | finance.yahoo.comEton Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 16, 2026 | markets.businessinsider.comSee More Headlines ETON Stock Analysis - Frequently Asked Questions How have ETON shares performed this year? Eton Pharmaceuticals' stock was trading at $16.91 at the start of the year. Since then, ETON shares have increased by 121.8% and is now trading at $37.50. How were Eton Pharmaceuticals' earnings last quarter? Eton Pharmaceuticals, Inc. (NASDAQ:ETON) posted its quarterly earnings data on Thursday, May, 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by $0.05. The firm earned $24.27 million during the quarter, compared to the consensus estimate of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative trailing twelve-month return on equity of 5.68%. Read the conference call transcript. When did Eton Pharmaceuticals IPO? Eton Pharmaceuticals (ETON) raised $22 million in an initial public offering (IPO) on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation acted as the underwriter for the IPO. How do I buy shares of Eton Pharmaceuticals? Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eton Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eton Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), CrowdStrike (CRWD) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/14/2026Today7/05/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 ETON's financial health is in the Green zone, according to TradeSmith. ETON has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ETON CIK1710340 Webwww.etonpharma.com Phone(847) 787-7361FaxN/AEmployees20Year Founded2017Price Target and Rating Average Price Target for Eton Pharmaceuticals$41.00 High Price Target$57.00 Low Price Target$31.00 Potential Upside/Downside+9.3%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.07) Trailing P/E RatioN/A Forward P/E Ratio50.00 P/E GrowthN/ANet Income-$4.60 million Net Margins-1.70% Pretax Margin-1.71% Return on Equity-5.68% Return on Assets-1.49% Debt Debt-to-Equity Ratio0.62 Current Ratio1.21 Quick Ratio0.88 Sales & Book Value Annual Sales$86.93 million Price / Sales11.82 Cash Flow$0.01 per share Price / Cash Flow7,234.91 Book Value$0.98 per share Price / Book38.27Miscellaneous Outstanding Shares27,392,000Free Float22,875,000Market Cap$1.03 billion OptionableOptionable Beta0.86 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ETON) was last updated on 7/5/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
